Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.0% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−397.8%−2826.8%522.6%−47310.8%
ROIC0.0%0.0%0.0%0.0%

Debt

It holds more cash than debt: net debt is −0.18× a year’s EBITDA.

Net debt / EBITDA
Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Net debt / EBITDA2.7×2.3×0.8×−0.2×

Cash cycle, in days

Customers pay in 0 days and suppliers are paid in 219. Suppliers fund 219 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle−1−4133−219
Days to pay suppliers13413894219
Days to be paid133971270

Per share, from Q4 FY25

Since Q4 FY25, per share: revenue has fallen 14.9%.

RevenueBook value
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue1.0×1.1×1.1×0.9×
Book value1.0×−0.3×−1.7×−1.8×
Sep '26 From the 10-Q filed 13 Nov Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
5.46 8.63 7.84 9.92
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(11.35) (18.04) (15.20) (17.32)
P/B ratio
0.00 0.00 0.00 24.88
Price to Tangible BV
0.00 0.00 0.00 24.88
EV/Sales
5.58 8.72 7.45 8.78
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(2.45) (4.48) (4.96) (4.76)
EV/FCF
(2.41) (4.41) (4.87) (4.67)
Quick Ratio
0.00 1.54 2.36 2.62
Current Ratio
1.69 1.65 2.42 2.68
Net Debt/EBITDA
— (0.18) 0.78 2.29
Debt/Assets
0.00% 77.12% 64.45% 50.53%
Debt/Equity
0.00 (2.11) (12.35) 4.08
Asset Turnover
0.31 0.52 0.48 0.31
Operating CF/Net income
1.09 0.86 1.00 1.13
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
— (18.78) (17.42) (13.55)
Research and Development Expense of Revenue
95.73% 34.61% 42.85% 81.06%
Selling, General and Administrative Expense of Revenue
323.03% 175.83% 157.99% 220.58%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
31.58% 15.02% 12.54% 34.02%
Graham Net Nets
(0.16) (0.08) (0.02) 0.04
Graham Number
0.56 0.58 0.24 0.00
Earnings Yield
(47.73%) (25.56%) (28.05%) (26.60%)
Free Cash Flow Yield
(42.42%) (22.91%) (19.52%) (18.96%)
Revenue per Share
0.01 0.03 0.03 0.02
Operating CF per Share
(0.04) (0.05) (0.05) (0.05)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.04) (0.05) (0.05) (0.05)
Cash per Share
0.00 0.13 0.18 0.26
Shareholders Equity per Share
(0.07) (0.07) (0.01) 0.04
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(0.07) (0.07) (0.01) 0.04
Free Cash Flow
(1.48) (1.82) (1.96) (1.77)
Working Capital
3.22 2.52 4.52 6.21
Net Current Asset Value
(2.64) (2.52) (0.52) 1.18
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
— 1.03 0.63 0.69
Average Payables
1.37 0.78 0.75 0.67
Average Assets
9.80 7.34 7.85 9.94
Average Common Equity
0.01 (1.46) 0.26 1.85

Fold the line items

Columns are period end dates · fundamentals updated 13 Nov 2026